PureTech Health PLC

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

RNS Number: 0542M PureTech Health PLC 13 July 2026 13 July 2026 PureTech Health plc PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) SURPASS-IPF is the

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

RNS Number: 7006K PureTech Health PLC 02 July 2026 2 July 2026 PureTech Health plc PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) PureTech launches

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

RNS Number: 7005K PureTech Health PLC 02 July 2026 2 July 2026 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION PureTech Health plc PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to

Results of Annual General Meeting

RNS Number: 8399H PureTech Health PLC 10 June 2026 10 June 2026 PureTech Health plc Results of Annual General Meeting The Annual General Meeting of PureTech Health plc (LSE: PRTC) (" PureTech " or the "Company") was held at 11 a.m. EDT / 4 p.m. BST on Wednesday, June 10, 2026.

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

RNS Number: 5025H PureTech Health PLC 09 June 2026 9 June 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) (" PureTech "

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

RNS Number: 1044E PureTech Health PLC 13 May 2026 13 May 2026 PureTech Health plc PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference Presentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to

PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

RNS Number: 7401C PureTech Health PLC 01 May 2026 1 May 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (" PureTech " or the "Company"), a hub-and-spoke biotherapeutics

PureTech Announces Annual Results for Year Ended December 31, 2025

RNS Number: 2953C PureTech Health PLC 29 April 2026 29 April 2026 PureTech Health plc PureTech Announces Annual Results for Year Ended December 31, 2025 Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics' Phase

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

RNS Number: 2947C PureTech Health PLC 29 April 2026 29 April 2026 PureTech Health plc PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange PureTech to maintain its primary listing on the London Stock

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

RNS Number: 9985B PureTech Health PLC 27 April 2026 27 April 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (" PureTech " or the

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

RNS Number: 4332B PureTech Health PLC 22 April 2026 22 April 2026 PureTech Health plc PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) Phase 1b dataset with

PureTech Health plc Notice of Results

RNS Number: 0765A PureTech Health PLC 13 April 2026 13 April 2026 PureTech Health plc Notice of Results PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (" PureTech " or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2025, on

PureTech Health Founded Entity Seaport Therapeutics Files Registration Statement for Proposed Initial Public Offering

RNS Number: 1579A PureTech Health PLC 13 April 2026 13 April 2026 PureTech Health plc PureTech Health Founded Entity Seaport Therapeutics Files Registration Statement for Proposed Initial Public Offering PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (" PureTech " or the "Company"), a

Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis (adjusted mean FVC difference 91 mL; p=0.02), approaching the lung function change expected in normal, healthy aging First industry-sponsored IPF

PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

PureTech Health plc PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo TM in Healthy Volunteers PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo TM (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans PureTech Health plc (Nasdaq: PRTC, LSE: PRTC)

An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans

PureTech to Present at the Leerink Partners Global Healthcare Conference